Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease

R. A. Kleinerman, L. G. Littlefield, R. E. Tarone, A. M. Sayer, D. L. Cookfair, J. Wactawski-Wende, P. D. Inskip, A. W. Block, K.h. Ramesh, J. D. Boice

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Excess leukemias have occurred after partial-body radiotherapy for cervical cancer and benign gynecological disease (BGD). However, the level of risk is nearly the same in both groups, about twofold, despite a tenfold difference in average dose to active bone marrow (8 Gy vs 0.7 Gy, respectively). High-dose cell killing has been postulated as one explanation for this apparent inconsistency. To examine whether chromosome aberration rates observed in lymphocytes many years after exposure might serve as population markers of cancer risk, blood samples were taken from 60 women treated for BGD (34 with radiation) and cytogenetic data compared with previous results from 96 women irradiated for cervical cancer. Remarkably, the rate of stable aberrations, which reflects nonlethal damage in surviving stem cells, was only slightly higher among the cancer patients. Thus the lower-dose regimens to treat benign disorders resulted in much higher aberration yields per unit dose than those for cervical cancer. Assuming that the fraction of cytogenetically aberrant stem cells that survive radiotherapy contributes to the leukemogenic process, these data are then consistent with the epidemiological observations of comparable overall leukemia risks seen in these two irradiated populations. Accordingly, for patient populations given partial-body radiotherapy, stable aberrations at a long time after exposure appear to serve as biomarkers of effective risk rather than as biomarkers of radiation dose received.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalRadiation Research
Volume139
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

chromosome aberrations
lymphocytes
Chromosome Aberrations
cancer
uterine cervical neoplasms
Uterine Cervical Neoplasms
Lymphocytes
radiotherapy
dosage
Radiotherapy
aberration
radiation therapy
leukemias
stem cells
biomarkers
Leukemia
leukemia
Stem Cells
Biomarkers
Radiation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Radiology Nuclear Medicine and imaging
  • Biophysics
  • Radiation

Cite this

Kleinerman, R. A., Littlefield, L. G., Tarone, R. E., Sayer, A. M., Cookfair, D. L., Wactawski-Wende, J., ... Boice, J. D. (1994). Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease. Radiation Research, 139(1), 40-46. https://doi.org/10.2307/3578730

Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease. / Kleinerman, R. A.; Littlefield, L. G.; Tarone, R. E.; Sayer, A. M.; Cookfair, D. L.; Wactawski-Wende, J.; Inskip, P. D.; Block, A. W.; Ramesh, K.h.; Boice, J. D.

In: Radiation Research, Vol. 139, No. 1, 1994, p. 40-46.

Research output: Contribution to journalArticle

Kleinerman, RA, Littlefield, LG, Tarone, RE, Sayer, AM, Cookfair, DL, Wactawski-Wende, J, Inskip, PD, Block, AW, Ramesh, KH & Boice, JD 1994, 'Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease', Radiation Research, vol. 139, no. 1, pp. 40-46. https://doi.org/10.2307/3578730
Kleinerman RA, Littlefield LG, Tarone RE, Sayer AM, Cookfair DL, Wactawski-Wende J et al. Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease. Radiation Research. 1994;139(1):40-46. https://doi.org/10.2307/3578730
Kleinerman, R. A. ; Littlefield, L. G. ; Tarone, R. E. ; Sayer, A. M. ; Cookfair, D. L. ; Wactawski-Wende, J. ; Inskip, P. D. ; Block, A. W. ; Ramesh, K.h. ; Boice, J. D. / Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease. In: Radiation Research. 1994 ; Vol. 139, No. 1. pp. 40-46.
@article{161a02ff9d4c481b8c0d34857b5a1fa3,
title = "Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease",
abstract = "Excess leukemias have occurred after partial-body radiotherapy for cervical cancer and benign gynecological disease (BGD). However, the level of risk is nearly the same in both groups, about twofold, despite a tenfold difference in average dose to active bone marrow (8 Gy vs 0.7 Gy, respectively). High-dose cell killing has been postulated as one explanation for this apparent inconsistency. To examine whether chromosome aberration rates observed in lymphocytes many years after exposure might serve as population markers of cancer risk, blood samples were taken from 60 women treated for BGD (34 with radiation) and cytogenetic data compared with previous results from 96 women irradiated for cervical cancer. Remarkably, the rate of stable aberrations, which reflects nonlethal damage in surviving stem cells, was only slightly higher among the cancer patients. Thus the lower-dose regimens to treat benign disorders resulted in much higher aberration yields per unit dose than those for cervical cancer. Assuming that the fraction of cytogenetically aberrant stem cells that survive radiotherapy contributes to the leukemogenic process, these data are then consistent with the epidemiological observations of comparable overall leukemia risks seen in these two irradiated populations. Accordingly, for patient populations given partial-body radiotherapy, stable aberrations at a long time after exposure appear to serve as biomarkers of effective risk rather than as biomarkers of radiation dose received.",
author = "Kleinerman, {R. A.} and Littlefield, {L. G.} and Tarone, {R. E.} and Sayer, {A. M.} and Cookfair, {D. L.} and J. Wactawski-Wende and Inskip, {P. D.} and Block, {A. W.} and K.h. Ramesh and Boice, {J. D.}",
year = "1994",
doi = "10.2307/3578730",
language = "English (US)",
volume = "139",
pages = "40--46",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "1",

}

TY - JOUR

T1 - Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease

AU - Kleinerman, R. A.

AU - Littlefield, L. G.

AU - Tarone, R. E.

AU - Sayer, A. M.

AU - Cookfair, D. L.

AU - Wactawski-Wende, J.

AU - Inskip, P. D.

AU - Block, A. W.

AU - Ramesh, K.h.

AU - Boice, J. D.

PY - 1994

Y1 - 1994

N2 - Excess leukemias have occurred after partial-body radiotherapy for cervical cancer and benign gynecological disease (BGD). However, the level of risk is nearly the same in both groups, about twofold, despite a tenfold difference in average dose to active bone marrow (8 Gy vs 0.7 Gy, respectively). High-dose cell killing has been postulated as one explanation for this apparent inconsistency. To examine whether chromosome aberration rates observed in lymphocytes many years after exposure might serve as population markers of cancer risk, blood samples were taken from 60 women treated for BGD (34 with radiation) and cytogenetic data compared with previous results from 96 women irradiated for cervical cancer. Remarkably, the rate of stable aberrations, which reflects nonlethal damage in surviving stem cells, was only slightly higher among the cancer patients. Thus the lower-dose regimens to treat benign disorders resulted in much higher aberration yields per unit dose than those for cervical cancer. Assuming that the fraction of cytogenetically aberrant stem cells that survive radiotherapy contributes to the leukemogenic process, these data are then consistent with the epidemiological observations of comparable overall leukemia risks seen in these two irradiated populations. Accordingly, for patient populations given partial-body radiotherapy, stable aberrations at a long time after exposure appear to serve as biomarkers of effective risk rather than as biomarkers of radiation dose received.

AB - Excess leukemias have occurred after partial-body radiotherapy for cervical cancer and benign gynecological disease (BGD). However, the level of risk is nearly the same in both groups, about twofold, despite a tenfold difference in average dose to active bone marrow (8 Gy vs 0.7 Gy, respectively). High-dose cell killing has been postulated as one explanation for this apparent inconsistency. To examine whether chromosome aberration rates observed in lymphocytes many years after exposure might serve as population markers of cancer risk, blood samples were taken from 60 women treated for BGD (34 with radiation) and cytogenetic data compared with previous results from 96 women irradiated for cervical cancer. Remarkably, the rate of stable aberrations, which reflects nonlethal damage in surviving stem cells, was only slightly higher among the cancer patients. Thus the lower-dose regimens to treat benign disorders resulted in much higher aberration yields per unit dose than those for cervical cancer. Assuming that the fraction of cytogenetically aberrant stem cells that survive radiotherapy contributes to the leukemogenic process, these data are then consistent with the epidemiological observations of comparable overall leukemia risks seen in these two irradiated populations. Accordingly, for patient populations given partial-body radiotherapy, stable aberrations at a long time after exposure appear to serve as biomarkers of effective risk rather than as biomarkers of radiation dose received.

UR - http://www.scopus.com/inward/record.url?scp=0027930464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027930464&partnerID=8YFLogxK

U2 - 10.2307/3578730

DO - 10.2307/3578730

M3 - Article

VL - 139

SP - 40

EP - 46

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 1

ER -